Ocuphire PharmaNASDAQ: OCUP

Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile Published data from two Phase 3 clinical trials demonstrated rapid reversal of pharmacologically-induced mydriasis with favorable safety profile

CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42 nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced it will participate in the Association for Research in Vision and Ophthalmology Special Interest Group (ARVO SIG) panel and the American Society of Retina Specialists (ASRS) 42 nd Annual Scientific Meeting, to highlight the potential of its lead oral candidate in development for diabetic retinopathy (DR).

FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company's lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, and the Retinal Imaging Biomarkers & Endpoints Summit meeting June 25-27 in Boston.

Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.

Viatris Inc. VTRS, and Ocuphire Pharma Inc. OCUP, +3.08% said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye dilations are conducted in the U.S. each year to examine the retina and for other routine check-ups, the companies said in a release, but the dilation can last up to 24 hours and side effects include light sensitivity and blurred vision.

Ocuphire Pharma Inc OCUP was plunging over 22% at one point on Friday after the company announced it appointed Rick Rodgers to the role of interim CEO. An SEC filing, which stated former CEO Mina Sooch was terminated suggested there could be an issue at the company, which sparked fear.

The consensus price target hints at a 257.1% upside potential for Ocuphire Pharma, Inc. (OCUP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ocuphire Pharma, Inc. (OCUP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.